Evidence map›Paper›PMID 40140152›Full record

ArticleDiscover oncology2025

In vitro study of effect of gold nanoparticles conjugated with triptorelin peptide on the radiosensitivity of breast cancer cells (MCF-7).

Elham Tavakkoli, Seyyed Mohammad Hashemi, Alireza Montazerabadi, Sara Khademi, Farzaneh Ghorbani, Sheyda Mohammadzadeh, Hosein Azimian

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elham TavakkoliMedical Physics Research Center, Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID http://orcid.org/0000-0001-9718-8182
Seyyed Mohammad HashemiMedical Physics Research Center, Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID https://orcid.org/0000-0001-6956-4603
Alireza MontazerabadiMedical Physics Research Center, Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID https://orcid.org/0000-0001-8768-0640
Sara KhademiDepartment of Radiology Technology, School of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID https://orcid.org/0000-0001-9823-8014
Farzaneh GhorbaniNanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID https://orcid.org/0000-0003-4191-9868
Sheyda MohammadzadehMedical Physics Research Center, Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Hosein AzimianMedical Physics Research Center, Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran. Azimianh@mums.ac.ir.ORCID https://orcid.org/0000-0003-2951-8228

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOne of the significant challenges in the field of radiation therapy for cancer cells is the damage to healthy tissues in the vicinity of the tumor. In light of the recent developments in nanotechnology, as well as the historical use of materials with high atomic number to enhance contrast in medical imaging, a potential solution was proposed: the use of targeted gold nanoparticles in conjunction with the triptorelin peptide to enhance the radiation sensitivity of MCF-7 cancer cells. Consequently, due to the presence of the triptorelin peptide receptor on the surface of MCF-7 cells, the nanoparticles are absorbed by the target cells in a targeted manner. By increasing the interaction between the nanoparticles and X-ray MeV 6, it was anticipated that there will be an increase in cell death and optimization of the treatment quality. METHODOLOGY: Following synthesis and combination with triptorelin peptide, gold nanoparticles coated with alginate were subjected to characterization tests. Subsequently, MTT and colony tests were conducted to ascertain the toxicity of the nanoparticles and the optimal dosage of the drug for use on MCF-7 cells. Subsequently, the cells were subjected to the colony assay to ascertain the level of radiation sensitivity. Following the culturing and treatment of the cells with a concentration of 20 μg/ml of nanoparticles, they were subjected to 2, 4, 6, and 8 Gy (Gray) of radiation. Following the incubation period, the resulting colonies were stained and counted. Finally, the flow cytometry test was employed by Annexin V PI kit to determine the extent of cell death caused by apoptosis.

resultsThe toxicity test finally indicated that a concentration of 20 μg/ml should be employed in the continuation of the study. The results of the colony assay, which was conducted to determine radiation sensitivity, revealed a dose enhancement factor (DEF) of 1.68, 2.32, 1.76 and 1.86, respectively, for radiation doses of 2, 4, 6 and 8 Gy. These findings were observed in the group that received the targeted nanoparticle in conjunction with radiation therapy, when compared to the group that received only radiation therapy. Additionally, the flow cytometry test yielded a synergistic effect of 5.63. The administration of gold nanoparticles in both forms was observed to result in a reduction in cell survival. However, the radio-sensitizing effect of targeted gold nanoparticles with triptorelin peptide was greater, which can be attributed to enhanced cellular uptake by breast cancer cells (MCF-7). Au-Triptorelin nanoparticles with their specific targeting increased radiosensitivity and increased apoptosis compared to the group that only received radiation.

conclusionThe results of the tests showed that Triptorelin-AuNPs nanoparticles have the ability to cause targeted sensitivity in MCF-7 cells with triptorelin peptide receptors.

Identifiers

PMID40140152
PMCPMC11947392

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.